CDK4 and lung cancer: Combinations of CDK4/6 and MEK inhibitors have also been shown to be synergistic in preclinical models of pancreatic, colorectal cancer and lung cancer, and several additional clinical trials evaluating CDK4/6 inhibitors with either MEK or ERK inhibitors are ongoing (NCT02022982, NCT02703571).